Straumann (SAUHF) & Biomerica (BMRA) Critical Contrast

Straumann (OTCMKTS:SAUHF) and Biomerica (NASDAQ:BMRA) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, valuation, analyst recommendations, earnings, institutional ownership, risk and dividends.

Profitability

This table compares Straumann and Biomerica’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Straumann N/A N/A N/A
Biomerica -31.75% -41.73% -34.79%

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Straumann and Biomerica, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Straumann 0 0 0 0 N/A
Biomerica 0 0 1 0 3.00

Biomerica has a consensus target price of $7.50, indicating a potential upside of 166.90%. Given Biomerica’s higher probable upside, analysts plainly believe Biomerica is more favorable than Straumann.

Institutional & Insider Ownership

1.5% of Biomerica shares are held by institutional investors. 26.8% of Biomerica shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Risk & Volatility

Straumann has a beta of 0.97, suggesting that its stock price is 3% less volatile than the S&P 500. Comparatively, Biomerica has a beta of -0.18, suggesting that its stock price is 118% less volatile than the S&P 500.

Earnings & Valuation

This table compares Straumann and Biomerica’s gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Straumann $1.13 billion 8.46 $277.36 million $17.82 33.80
Biomerica $5.56 million 4.56 -$1.46 million ($0.17) -16.53

Straumann has higher revenue and earnings than Biomerica. Biomerica is trading at a lower price-to-earnings ratio than Straumann, indicating that it is currently the more affordable of the two stocks.

Summary

Straumann beats Biomerica on 8 of the 12 factors compared between the two stocks.

About Straumann

Straumann Holding AG provides tooth replacement solutions worldwide. It researches, develops, manufactures, and supplies dental implants, instruments, CADCAM prosthetics, biomaterials, and digital solutions for use in tooth replacement and restoration or to prevent tooth loss. The company offers replacement solutions, including soft tissue level and bone level implants; SLActive surface for bone formation; Roxolid for use in dental implantology; and ceramic implants. It also provides prosthetic components and tools, as well as precision instruments, guided surgery tools, and handling components. In addition, the company offers digital solutions, including guided surgery, intra-oral scanning, and CADCAM; and oral tissue regeneration solutions comprising Emdogain, bone substitutes, membranes, soft tissue grafts, and fleeces. Further, it provides training and education services to its customers. The company offers its products to general dentists, specialists, and dental technicians/laboratories in approximately 100 countries through a network of distribution subsidiaries and partners. Straumann Holding AG was founded in 1954 and is headquartered in Basel, Switzerland.

About Biomerica

Biomerica, Inc., together with its subsidiaries, develops, manufactures, and markets medical diagnostic products for the early detection and monitoring of chronic diseases and medical conditions. The company's diagnostic test kits are used to analyze blood, urine, or fecal samples from patients in the diagnosis of various diseases and other medical complications; or to measure the level of specific hormones, antibodies, antigens, or other substances, which exist in the human body in extremely small concentrations. It primarily focuses on products for gastrointestinal diseases, food intolerances, diabetes, and various esoteric tests. The company offers its products to hospital and clinical laboratories, medical research institutions, medical schools, pharmaceutical companies, chain drugstores, wholesalers, and physicians' offices, as well as to distributors. It operates in Europe, the United States, Asia, South America, the Middle East, and internationally. Biomerica, Inc. was founded in 1971 and is headquartered in Irvine, California.

Receive News & Ratings for Straumann Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Straumann and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit